Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy

C.R. Garrett; L.L. Siu; A. El-Khoueiry; J. Buter; C.M. Rocha-Lima; J. Marshall; P. LoRusso; P. Major; J. Chemidlin; O. Mokliatchouk; L. Velasquez; W. Hayes; D. Feltquate; S. Syed; S. Ford; G. Kollia; S. Galbraith; D.S.A. Nuyten

doi:10.1038/bjc.2011.182

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy

C.R. Garrett
, L.L. Siu
, A. El-Khoueiry
, J. Buter
, C.M. Rocha-Lima
, J. Marshall
, P. LoRusso
, P. Major
, J. Chemidlin
, O. Mokliatchouk
, L. Velasquez
, W. Hayes
, D. Feltquate
, S. Syed
, S. Ford
, G. Kollia
, S. Galbraith
, D.S.A. Nuyten

Affiliatie VU

Research output: Contribution to journal › Article › Academic › peer-review

15 Downloads (Pure)

Original language	Undefined/Unknown
Pages (from-to)	44-52
Journal	British journal of cancer
Volume	105
Issue number	1
DOIs	https://doi.org/10.1038/bjc.2011.182
Publication status	Published - 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/bjc.2011.182

282670Final published version, 387 KB

Cite this

Garrett, C. R., Siu, L. L., El-Khoueiry, A., Buter, J., Rocha-Lima, C. M., Marshall, J., LoRusso, P., Major, P., Chemidlin, J., Mokliatchouk, O., Velasquez, L., Hayes, W., Feltquate, D., Syed, S., Ford, S., Kollia, G., Galbraith, S., & Nuyten, D. S. A. (2011). Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. British journal of cancer, 105(1), 44-52. https://doi.org/10.1038/bjc.2011.182

@article{5da965dbf2624bad967a163458755523,

title = "Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy",

author = "C.R. Garrett and L.L. Siu and A. El-Khoueiry and J. Buter and C.M. Rocha-Lima and J. Marshall and P. LoRusso and P. Major and J. Chemidlin and O. Mokliatchouk and L. Velasquez and W. Hayes and D. Feltquate and S. Syed and S. Ford and G. Kollia and S. Galbraith and D.S.A. Nuyten",

year = "2011",

doi = "10.1038/bjc.2011.182",

language = "Undefined/Unknown",

volume = "105",

pages = "44--52",

journal = "British journal of cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "1",

}

Garrett, CR, Siu, LL, El-Khoueiry, A, Buter, J, Rocha-Lima, CM, Marshall, J, LoRusso, P, Major, P, Chemidlin, J, Mokliatchouk, O, Velasquez, L, Hayes, W, Feltquate, D, Syed, S, Ford, S, Kollia, G, Galbraith, S & Nuyten, DSA 2011, 'Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy', British journal of cancer, vol. 105, no. 1, pp. 44-52. https://doi.org/10.1038/bjc.2011.182

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. / Garrett, C.R.; Siu, L.L.; El-Khoueiry, A. et al.
In: British journal of cancer, Vol. 105, No. 1, 2011, p. 44-52.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy

AU - Garrett, C.R.

AU - Siu, L.L.

AU - El-Khoueiry, A.

AU - Buter, J.

AU - Rocha-Lima, C.M.

AU - Marshall, J.

AU - LoRusso, P.

AU - Major, P.

AU - Chemidlin, J.

AU - Mokliatchouk, O.

AU - Velasquez, L.

AU - Hayes, W.

AU - Feltquate, D.

AU - Syed, S.

AU - Ford, S.

AU - Kollia, G.

AU - Galbraith, S.

AU - Nuyten, D.S.A.

PY - 2011

Y1 - 2011

U2 - 10.1038/bjc.2011.182

DO - 10.1038/bjc.2011.182

M3 - Article

C2 - 21629245

SN - 0007-0920

VL - 105

SP - 44

EP - 52

JO - British journal of cancer

JF - British journal of cancer

IS - 1

ER -

Garrett CR, Siu LL, El-Khoueiry A, Buter J, Rocha-Lima CM, Marshall J et al. Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. British journal of cancer. 2011;105(1):44-52. doi: 10.1038/bjc.2011.182